In acute myeloid leukemia (AML), one of the most common types of leukemia, silvestrol (14) was shown to exhibit significant in vivo and in vitro activities through a novel mechanism resulting in inhibition of FLT3 (FMS-like tyrosine kinase receptor-3) and miR-155 (microRNA) expression (Alachkar et al. 2013). The gene discussed is FLT3; the disease is acute myeloid leukemia.